MWNA
ZYNE

Marshall Wace North America’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Marshall Wace North America’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-76,339
Closed -$744K – 1473
2018
Q2 		$744K Buy
+76,339
New +$782K ﹤0.01% 1004
2017
Q3 		– Sell
-391,926
Closed -$6.66M – 1568
2017
Q2 		$6.66M Sell
391,926
-76,183
-16% -$1.51M 0.05% 415
2017
Q1 		$9.36M Buy
+468,109
New +$9.3M 0.07% 285

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace North America's ZYNE Position: Q3 2018 in Review

Marshall Wace North America sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2018, closing a stake of 76,339 shares — an estimated $744K sold.

Marshall Wace North America first reported a position in ZYNE in Q1 2017 and held it in 3 quarters. The position peaked at $9.36M in Q1 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2018.

  • Marshall Wace North America reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 76,339 Zynerba Pharmaceuticals, Inc shares in Q3 2018, an estimated $744K.
  • Marshall Wace North America first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 3 quarters.
  • Marshall Wace North America's Zynerba Pharmaceuticals, Inc position peaked at $9.36M in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.